Related Experiment Videos
Gastrointestinal endocrine tumours. Gastrinoma
1Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20891, USA.
Bailliere'S Clinical Gastroenterology
|December 1, 1996
Summary
Zollinger-Ellison syndrome (ZES) management has evolved from controlling acid to targeting gastrinomas. Recent research offers insights into gastrinoma behavior, surgical roles, and molecular causes.
Area of Science:
- Endocrinology
- Gastroenterology
- Surgical Oncology
Background:
- Zollinger-Ellison syndrome (ZES) characterized by gastric acid hypersecretion was first described in 1955.
- Significant progress has been made in understanding ZES pathogenesis, natural history, and diagnosis.
- Medical control of gastric acid hypersecretory states is now achievable in most patients.
Purpose of the Study:
- To review recent advances in the understanding and management of Zollinger-Ellison syndrome.
- To highlight the shift in treatment focus towards gastrinoma management.
- To discuss insights into gastrinoma natural history, invasiveness, and molecular pathogenesis.
Main Methods:
- Review of recent scientific literature and clinical studies.
- Analysis of advances in diagnosis and tumor localization techniques.
- Evaluation of current and emerging treatment strategies for gastrinomas.
Main Results:
- Gastric acid hypersecretory states in ZES are now medically manageable.
- Focus is shifting to the management of the primary tumor, the gastrinoma.
- New insights into gastrinoma natural history, invasiveness factors, and molecular abnormalities are emerging.
Conclusions:
- Management of Zollinger-Ellison syndrome has significantly advanced, with medical control of hyperacidity now standard.
- The primary therapeutic challenge is now the effective management of gastrinomas.
- Ongoing research is crucial for understanding gastrinoma behavior and improving patient outcomes.